active control

Phase 3Small molecule

Biogen

active control is one of 114 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

UrticariaActive, not recruiting

Herpes ZosterActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

UrticariaPhase 3

Active, not recruiting

Herpes ZosterPhase 1

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

active control

Biogen

Phase 3

1 2

Byetta

AstraZeneca

Preclinical

20 3

Tanzeum

GSK

Preclinical

10 4

Insulin 320

Novo Nordisk

Preclinical

43 5

Adenocard

Astellas

Preclinical

1 6

Cipro

Myrbetriq

Golytely

Lantus

6 10

Lixisenatide

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy1 trial

A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

Completed·SShanghai SIMR Biotechnology Co., Ltd.·Phase 1/2·NCT04494815·24 enrolled

Bacterial Infection1 trial

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Completed· Merck & Co. logo

Merck & Co.·Phase 2/3·NCT03969901·115 enrolled

Urticaria1 trial

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

Completed·JJDP Therapeutics, Inc.·Phase 3·NCT02935699·262 enrolled

Herpes Zoster1 trial

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

Completed·IImmorna Biotherapeutics, Inc.·Phase 1·NCT05871541·75 enrolled

Adult1 trial

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

Completed· Biogen logo

Biogen·Phase 1·NCT02201849·104 enrolled

2 more indications

Type 2 Diabetes Mellitus1 trial

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

Completed·IInVasc Therapeutics, Inc.·Phase 2·NCT01398423·88 enrolled

MPA1 trial

Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

Completed·VVanda Pharmaceuticals·Phase 1·NCT06323655·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for active control. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — active control compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for active control. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Biogen

active control

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy1 trial

Bacterial Infection1 trial

Urticaria1 trial

Herpes Zoster1 trial

Adult1 trial

Type 2 Diabetes Mellitus1 trial

MPA1 trial

References

Drug Info

Quick Facts

Related News